AU2001253070A1 - Isoflavones for treatment of obesity - Google Patents

Isoflavones for treatment of obesity

Info

Publication number
AU2001253070A1
AU2001253070A1 AU2001253070A AU5307001A AU2001253070A1 AU 2001253070 A1 AU2001253070 A1 AU 2001253070A1 AU 2001253070 A AU2001253070 A AU 2001253070A AU 5307001 A AU5307001 A AU 5307001A AU 2001253070 A1 AU2001253070 A1 AU 2001253070A1
Authority
AU
Australia
Prior art keywords
isoflavones
obesity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253070A
Inventor
Jonathan Ingram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001253070A1 publication Critical patent/AU2001253070A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001253070A 2000-03-31 2001-03-30 Isoflavones for treatment of obesity Abandoned AU2001253070A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19346300P 2000-03-31 2000-03-31
US60193463 2000-03-31
PCT/US2001/010560 WO2001074345A2 (en) 2000-03-31 2001-03-30 Isoflavones for treatment of obesity

Publications (1)

Publication Number Publication Date
AU2001253070A1 true AU2001253070A1 (en) 2001-10-15

Family

ID=22713739

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253070A Abandoned AU2001253070A1 (en) 2000-03-31 2001-03-30 Isoflavones for treatment of obesity

Country Status (3)

Country Link
US (1) US20020010141A1 (en)
AU (1) AU2001253070A1 (en)
WO (1) WO2001074345A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037100A1 (en) * 1998-03-19 2005-02-17 Bionorica Ag Utilization of extracts from iris plants, cimicifuga racemose and tectorigenin as an estrogen-like organ-selective medicament without uterotropic
EP1281392A1 (en) * 2001-08-02 2003-02-05 Cognis France S.A. Cosmetic or/and pharmaceutical compositions containing plant extracts
DE10146159A1 (en) * 2001-09-19 2003-04-10 Bionorica Ag Use of extracts from Cimicifuga species as an organ-selective drug for the treatment of sex hormone-dependent diseases of the urogenital tract
DE10206390A1 (en) * 2002-02-15 2003-08-28 Bionorica Ag Use of phytoestrogen-containing extracts that selectively modulate the estrogen receptor beta
US20050090457A1 (en) * 2002-02-15 2005-04-28 N.V. Nutricia Method of treating mammals with genistein and/or genistein analogues
AUPS104402A0 (en) * 2002-03-12 2002-04-11 Redfern Optical Components Pty Ltd Multi-layered structure characterisation
FR2841470B1 (en) * 2002-06-27 2006-01-13 Pharmascience Lab USE OF ISOFLAVONES FOR THE PREPARATION OF TOPICAL COMPOSITIONS USEFUL FOR PROMOTING SLIMMING AND ASSOCIATED COSMETIC TREATMENT METHOD
US8580846B2 (en) * 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US20040097429A1 (en) * 2002-11-18 2004-05-20 Nieuwenhuizen Arie Gijsbert Method for the reduction of the mammalian appetite
KR100994632B1 (en) * 2002-12-27 2010-11-15 (주)아모레퍼시픽 Screening method of chemical substance that specifically regulates expression of CT-1 gene in transcriptional step and CT-1 expression promoter comprising genistein detected by the method as an active ingredient
KR100520408B1 (en) * 2003-03-25 2005-10-10 주식회사 태평양 Compositions for the improvement of obesity
JP2006524236A (en) * 2003-04-24 2006-10-26 アモレパシフィック コーポレーション Slimming composition
ES2559777T3 (en) * 2004-03-17 2016-02-15 Nestec S.A. Compositions and methods to reduce or prevent obesity
US20060039971A1 (en) * 2004-08-19 2006-02-23 Lee Robert E Effervescent composition including alternative hormone replacement therapy agent
US20080138453A1 (en) * 2005-03-07 2008-06-12 Jumpsun Bio-Medicine (Shanghai) Co., Ltd. Chickpea Extracts As Therapeutic Agents And Foods In The Treatment And Prevention Of Obesity And Non-Insulin-Depenent Diabetes
CN100482243C (en) * 2005-03-07 2009-04-29 骏神生物医学（上海）有限公司 Application of olecranone bean extraction in preparation of food for preventing and treating obesity and type II diabetes
AU2006310690B2 (en) * 2005-11-02 2012-05-31 Société des Produits Nestlé S.A. Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use
US8367072B2 (en) * 2006-12-08 2013-02-05 Polifenoles Naturales, S.L. Composition for treating obesity and method of using the same
FR2999080B1 (en) * 2012-12-11 2015-03-20 Isp Investments Inc COSMETIC USE OF THE ASSOCIATION OF CARBOHYL AND CAFFEINE GERM EXTRACT AS A SLIMMING ACTIVE AGENT
US10842809B2 (en) 2016-12-16 2020-11-24 Hills Pet Nutrition, Inc. Pet food compositions
US20240085431A1 (en) * 2022-09-13 2024-03-14 Société des Produits Nestlé S.A. Methods for providing and determining an efficacious weight loss diet for a canine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864362A (en) * 1970-05-27 1975-02-04 Chinoin Gyogyszer Es Vegyeszet Iso flavones
GB1351880A (en) * 1971-10-20 1974-05-01 Chinoin Gyogyszer Es Vegyeszet Metabolism-regulating derivatives
DE69333624T2 (en) * 1992-05-19 2005-09-15 Novogen Research Pty. Ltd., North Ryde USE OF ISOFLAVON PHYTO-ESTROGEN EXTRACTS OF SOY OR CLOVER
EP0906029B1 (en) * 1996-04-09 2002-08-14 E.I. Du Pont De Nemours And Company Isoflavone-enriched soy protein product and method for its manufacture
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
JP2829387B2 (en) * 1996-09-13 1998-11-25 農林水産省四国農業試験場長 Composition for promoting lipolysis in fat cells
JPH11116487A (en) * 1997-10-11 1999-04-27 Chin Tadahide Material for normalizing blood sugar
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
JPH11228430A (en) * 1998-02-20 1999-08-24 Asahi Breweries Ltd Lipolysis accelerator
ATE264093T1 (en) * 1998-07-16 2004-04-15 Aaron Tabor SOY PREPARATIONS AND THEIR USE FOR HEALTH PROMOTION
HUP0200117A2 (en) * 1999-02-24 2002-05-29 Geza Bruckner Dietary compositions and methods
FR2803747B1 (en) * 2000-01-18 2003-12-26 Pharmascience Lab USE OF ISOFLAVONES AND / OR EXTRACTS OF AFRICAN PLUM IN PHARMACY, COSMETICS AND AS A FOOD ADDITIVE.

Also Published As

Publication number Publication date
WO2001074345A3 (en) 2002-03-21
WO2001074345A2 (en) 2001-10-11
US20020010141A1 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
AU2001253070A1 (en) Isoflavones for treatment of obesity
AU2001266068A1 (en) Treatment of mineral substrates
AU2002223827A1 (en) Well treatment
AU2002257936A1 (en) Methods of well treatment
AU2001286983A1 (en) Method of treatment
AU2002231206A1 (en) Treatment of depression
AU2003264673A1 (en) Use of isoflavones for promoting slimming
AU2001277534A1 (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity
AU2002236781A1 (en) Treatment for snoring
AU2002217447A1 (en) Apparatus for lipolysis for aesthetic treatment
AU7750100A (en) Method for the treatment of obesity
AUPR731901A0 (en) Method of treatment
AU2001245414A1 (en) Treatment of allergies
AU2002225327A1 (en) Apparatus for aesthetic treatment
AU2001262177A1 (en) Method of treatment
AU2001281465A1 (en) Treatment of rosacea
AU2000272704A1 (en) Use of compounds for the treatment of obesity
AU2001253560A1 (en) Methods of treatment
AU2002323430A1 (en) Methods of treating obesity
HK1057160A (en) Obesity treatment aid
HK1057997A (en) Treatment of osteoporosis
GB0001861D0 (en) Method for the treatment of obesity
HK1056502A (en) Methods of treatment
AUPQ949500A0 (en) Method of treatment
AUPQ662500A0 (en) Method of treatment